H-Ras gene takes part to the host immune response to COVID-19.


Journal

Cell death discovery
ISSN: 2058-7716
Titre abrégé: Cell Death Discov
Pays: United States
ID NLM: 101665035

Informations de publication

Date de publication:
25 Jun 2021
Historique:
received: 06 04 2021
accepted: 29 05 2021
revised: 06 05 2021
entrez: 6 7 2021
pubmed: 7 7 2021
medline: 7 7 2021
Statut: epublish

Résumé

Ras gene family members play a relevant role in cancer, especially when they are mutated. However, they may play additional roles in other conditions beside cancer. We performed gene expression analysis using the NanoString PanCancer IO 360 panel in the peripheral blood mononuclear cell (PBMC) of six COVID-19 patients and we found that H-Ras gene was significantly upregulated, while both K-Ras and N-Ras genes were downregulated. In particular, H-Ras gene upregulation was more evident in COVID-19 patients with a more severe disease. We compared our results with those obtained by analyzing two different and independent datasets, including a total of 53 COVID-19 patients, in which the gene expression analysis was performed using the Immunology_V2 panel. Comparative analysis of the H-Ras gene expression in these patients confirmed our preliminary results. In both of them, in fact, we were able to confirm the upregulation of the expression of the H-Ras gene. The exact role of this specific upregulation of the H-Ras gene in response to SARS-CoV-2 infection and its possible role in cancer still remains to be elucidated. In conclusion, H-Ras gene participates to the host immune response to SARS-CoV-2 virus infection, especially in patients affected by the most severe form of the COVID-19.

Identifiants

pubmed: 34226505
doi: 10.1038/s41420-021-00541-w
pii: 10.1038/s41420-021-00541-w
pmc: PMC8256395
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

158

Références

Pharmacology. 2021;106(1-2):119-122
pubmed: 33011728
Curr Opin Pharmacol. 2012 Aug;12(4):458-63
pubmed: 22401931
Viruses. 2021 Jan 27;13(2):
pubmed: 33513748
J Hum Genet. 2016 Jan;61(1):33-9
pubmed: 26446362
Am J Respir Cell Mol Biol. 2009 May;40(5):610-9
pubmed: 18978302
Nat Microbiol. 2019 Feb;4(2):216-225
pubmed: 30420785
3 Biotech. 2020 Oct;10(10):422
pubmed: 33251083
J Transl Med. 2021 Apr 1;19(1):139
pubmed: 33794925
Front Oncol. 2021 Jan 25;10:582901
pubmed: 33585201
Science. 2020 Aug 7;369(6504):718-724
pubmed: 32661059
Arch Virol. 2021 Mar;166(3):675-696
pubmed: 33462671
J Virol. 2011 May;85(9):4399-408
pubmed: 21307189

Auteurs

Salvatore Sciacchitano (S)

Department of Clinical and Molecular Medicine, Sapienza University of Rome, via di Grottarossa 1035-1039, 00189, Rome, Italy.
Laboratory of Biomedical Research, Niccolò Cusano University Foundation, Rome, Italy.

Andrea Sacconi (A)

UOSD Clinical Trial Center, Biostatistics and Bioinformatics, IRCCS Regina Elena National Cancer Institute, Rome, Italy.

Claudia De Vitis (C)

Department of Clinical and Molecular Medicine, Sapienza University of Rome, via di Grottarossa 1035-1039, 00189, Rome, Italy.

Giovanni Blandino (G)

UOSD Clinical Trial Center, Biostatistics and Bioinformatics, IRCCS Regina Elena National Cancer Institute, Rome, Italy.

Giulia Piaggio (G)

UOSD SAFU, Department of Research, Diagnosis and Innovative Technologies, IRCCS-Regina Elena National Cancer Institute, Roma, Italy.

Valentina Salvati (V)

UOSD SAFU, Department of Research, Diagnosis and Innovative Technologies, IRCCS-Regina Elena National Cancer Institute, Roma, Italy.

Christian Napoli (C)

Department of Medical Surgical Sciences and Translational Medicine, Sapienza University of Rome, via di Grottarossa 1035/1039, 00189, Rome, Italy.

Paolo Marchetti (P)

Department of Clinical and Molecular Medicine, Sapienza University of Rome, via di Grottarossa 1035-1039, 00189, Rome, Italy.
Medical Oncology Sant'Andrea Hospital, University La Sapienza, via di Grottarossa 1035-1039, 00189, Rome, Italy.

Beatrice Salimbeni Taurelli (BS)

Medical Oncology Sant'Andrea Hospital, University La Sapienza, via di Grottarossa 1035-1039, 00189, Rome, Italy.

Flaminia Coluzzi (F)

Unit of Anesthesia, Intensive Care and Pain Medicine, Sant'Andrea University Hospital, Rome, Italy.

Monica Rocco (M)

Unit of Anesthesia, Intensive Care and Pain Medicine, Sant'Andrea University Hospital, Rome, Italy.

Andrea Vecchione (A)

Department of Clinical and Molecular Medicine, Sapienza University of Rome, via di Grottarossa 1035-1039, 00189, Rome, Italy.

Paolo Anibaldi (P)

Medical Direction Sant'Andrea Hospital, University La Sapienza, 00189, Rome, Italy.

Adriano Marcolongo (A)

General Direction Sant'Andrea Hospital, University La Sapienza, 00189, Rome, Italy.

Gennaro Ciliberto (G)

Scientific Directorate, IRCSS Regina Elena National Cancer Institute, 00144, Rome, Italy.

Rita Mancini (R)

Department of Clinical and Molecular Medicine, Sapienza University of Rome, via di Grottarossa 1035-1039, 00189, Rome, Italy.

Carlo Capalbo (C)

Medical Oncology Sant'Andrea Hospital, University La Sapienza, via di Grottarossa 1035-1039, 00189, Rome, Italy. carlo.capalbo@uniroma1.it.
Department of Molecular Medicine, University La Sapienza, 00189, Rome, Italy. carlo.capalbo@uniroma1.it.

Classifications MeSH